Neshima is developing life-saving treatments for severe lung diseases using LiFT™, a patented foam-based delivery platform. LiFT™ enables deep and uniform therapeutic delivery to the alveoli, overcoming the limitations of inhalers, nebulizers, and intravenous treatments. Our lead applications include a regenerative cell therapy for COPD. As a cost-effective PoC we are also developing an ICU-delivered antibiotic treatment for antimicrobial-resistant infections. A fully functional prototype has been tested in large animals. Neshima is targeting a $10 billion U.S. market with a B2B model.
Cumulative Funding Raised Over Time ($)
Employees Over Time
Neshima Medical Climate Tech relevance
null
Latest News
No Data, yet.
Sorry, no content found under this section.
Apr 30, 2020
www.haaretz.co.il
ללא מכונות הנשמה: חוקרים ישראלים מפתחים שיטות פורצות דרך להצלת חולי קורונה
undefined
Apr 16, 2020
cordis.europa.eu
Pioneering foam therapy offers hope to lung patients LIFT Project Results in brief H2020 CORDIS European Commission